Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 576

1.

Cytoreductive nephrectomy in the current treatment algorithm.

Kuusk T, Szabados B, Liu WK, Powles T, Bex A.

Ther Adv Med Oncol. 2019 Sep 27;11:1758835919879026. doi: 10.1177/1758835919879026. eCollection 2019. Review.

PMID:
31632471
2.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Kamoun A, Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group.

Eur Urol. 2019 Sep 26. pii: S0302-2838(19)30695-5. doi: 10.1016/j.eururo.2019.09.006. [Epub ahead of print]

3.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
4.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
5.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B.

Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Review.

PMID:
31377308
6.

PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S.

Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.

PMID:
31371341
7.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Sep;119:200-201. doi: 10.1016/j.ejca.2019.04.012. Epub 2019 Jul 11. No abstract available.

PMID:
31301937
8.

Molecular and histopathology directed therapy for advanced bladder cancer.

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M.

Nat Rev Urol. 2019 Aug;16(8):465-483. doi: 10.1038/s41585-019-0208-0. Epub 2019 Jul 9. Review.

PMID:
31289379
9.

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M.

Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013.

10.

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Rini BI, Powles T.

N Engl J Med. 2019 Jun 27;380(26):2582. doi: 10.1056/NEJMc1905518. No abstract available.

PMID:
31242371
11.

Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.

Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H.

Eur Urol. 2019 Sep;76(3):368-380. doi: 10.1016/j.eururo.2019.05.041. Epub 2019 Jun 21. Review.

PMID:
31235192
12.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.

PMID:
31227307
13.

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR.

Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6.

14.

Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K.

Eur Urol Oncol. 2019 Jun 3. pii: S2588-9311(19)30054-9. doi: 10.1016/j.euo.2019.04.005. [Epub ahead of print] Review.

PMID:
31171501
15.

Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition.

Lam JM, Liu WK, Powles T, Tang YZ, Szabados B.

Eur Urol Oncol. 2019 Apr 9. pii: S2588-9311(19)30032-X. doi: 10.1016/j.euo.2019.03.001. [Epub ahead of print]

PMID:
31151926
16.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A.

Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.

PMID:
31151678
17.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 Sep 15;125(18):3155-3163. doi: 10.1002/cncr.32169. Epub 2019 May 31.

PMID:
31150110
18.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30. Review.

PMID:
31102620
19.

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ.

J Pathol. 2019 Oct;249(2):151-165. doi: 10.1002/path.5306. Epub 2019 Jun 24. Review.

20.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
21.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M.

J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3.

22.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD.

Oncologist. 2019 Oct;24(10):1348-1355. doi: 10.1634/theoncologist.2018-0739. Epub 2019 Apr 1.

PMID:
30936379
23.

The adjuvant treatment of kidney cancer: a multidisciplinary outlook.

Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A.

Nat Rev Nephrol. 2019 Jul;15(7):423-433. doi: 10.1038/s41581-019-0131-x. Review.

PMID:
30914797
24.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

25.

Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Scand J Urol. 2019 Feb;53(1):14-20. doi: 10.1080/21681805.2019.1588919. Epub 2019 Mar 25.

PMID:
30907214
26.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A.

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

PMID:
30803729
27.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
28.

Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T.

Eur Urol Focus. 2019 Feb 6. pii: S2405-4569(19)30010-0. doi: 10.1016/j.euf.2019.01.010. [Epub ahead of print]

PMID:
30738795
29.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

30.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Erratum in: Eur J Cancer. 2019 Sep;119:200-201.

PMID:
30616146
31.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J.

JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271.

PMID:
30543350
32.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
33.

Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.

Eur Urol. 2019 Mar;75(3):e82-e83. doi: 10.1016/j.eururo.2018.11.032. Epub 2018 Nov 28. No abstract available.

PMID:
30502102
34.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

35.

Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A.

Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25.

PMID:
30467042
36.

Sunitinib Alone or after Nephrectomy in Renal Cancer.

Bex A, Powles T, Haanen J.

N Engl J Med. 2018 Nov 8;379(19):1877-8. doi: 10.1056/NEJMc1811532. No abstract available.

PMID:
30406978
37.

Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment.

Tshuma N, Glynn N, Evanson J, Powles T, Drake WM.

Eur J Cancer. 2018 Nov;104:247-249. doi: 10.1016/j.ejca.2018.09.016. Epub 2018 Oct 28. No abstract available.

PMID:
30377030
38.

Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer.

Powles T, Rini B.

J Clin Oncol. 2018 Oct 29:JCO2018792655. doi: 10.1200/JCO.2018.79.2655. [Epub ahead of print]

PMID:
30372383
39.

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A.

Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13. Review.

PMID:
30327274
40.

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR).

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A.

Eur Urol. 2019 Feb;75(2):261-264. doi: 10.1016/j.eururo.2018.10.007. Epub 2018 Oct 11.

PMID:
30318330
41.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
42.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS.

Eur Urol. 2019 Mar;75(3):435-444. doi: 10.1016/j.eururo.2018.09.022. Epub 2018 Sep 28. Review.

PMID:
30274701
43.

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs TP, Kelly JD, Powles T, Peggs KS, Chain BM, Linch MD, Quezada SA.

J Exp Med. 2018 Nov 5;215(11):2748-2759. doi: 10.1084/jem.20181003. Epub 2018 Sep 26.

44.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
45.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
46.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

47.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
48.

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B, Fenwick K, Herman B, Matthews N, O'Leary B, Hulkki S, Gonzalez De Castro D, Patel A, Wotherspoon A, Okachi A, Rana I, Begum R, Davies MN, Powles T, von Loga K, Hubank M, Turner N, Watkins D, Chau I, Cunningham D, Lise S, Starling N, Gerlinger M.

Clin Chem. 2018 Nov;64(11):1626-1635. doi: 10.1373/clinchem.2018.289629. Epub 2018 Aug 27.

49.

Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.

Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20. No abstract available.

PMID:
30138772
50.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631

Supplemental Content

Loading ...
Support Center